Cholangiocarcinoma, or bile duct cancer, is an aggressive and often late-diagnosed cancer of the biliary tract. Early stages typically present with few or nonspecific symptoms, making early molecular detection critical for improving outcomes.

The Cholangio Immunocarcinogenic Assay evaluates immune and molecular biomarker activity linked to bile duct carcinogenesis. By detecting subtle immunocarcinogenic and prometastatic patterns, this test supports early risk identification, precision therapy guidance, and recurrence monitoring.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Cholangio Immunocarcinogenic Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Detection Support

Identifies immune and molecular disruptions associated with bile duct cancer initiation.

Precision Oncology Tool

Provides data to support targeted therapy and immunotherapy strategies.

Monitoring Capability

Tracks molecular shifts in patients under treatment or surveillance.

Complementary Evidence

Adds immune-molecular insight to imaging and pathology results.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Cholangio Immunocarcinogenic Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and bile duct tumor progression:

  • Immune checkpoint proteins (PD-L1, CTLA-4 pathways)

  • Angiogenesis factors (VEGF, FGF) driving bile duct tumor growth

  • Inflammatory cytokines (IL-6, TNF-α, CRP)

  • Tumor microenvironment and prometastatic activity indicators

  • Fibrosis and biliary tract stress biomarkers

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers securely via Persona Biomed’s portal.

02

Sample Collection

Blood draw performed at a certified lab or through mobile phlebotomy.

03

Laboratory Analysis

Assays evaluate immunocarcinogenic and prometastatic activity relevant to bile duct cancer.

04

Results Delivery

Comprehensive report provided in the patient portal, including physician-ready detail and AI-supported patient summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Patients with known risk factors such as primary sclerosing cholangitis (PSC), liver flukes, or chronic biliary inflammation.

  • Individuals with abnormal liver or bile duct imaging results.

  • Patients undergoing treatment for cholangiocarcinoma needing molecular monitoring.

  • Survivors requiring recurrence risk assessment and long-term follow-up.

Register Now for Cholangio Immunocarcinogenic Assay

Register now for the Cholangio Immunocarcinogenic Assay to uncover immune and molecular signals of bile duct cancer and guide precision care.

Register now